Skip to content

Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury

Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01122225
Acronym
NESAKI
Enrollment
50
Registered
2010-05-13
Start date
2009-07-31
Completion date
2010-06-30
Last updated
2010-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Failure

Keywords

septic shock, medical intensive care

Brief summary

Acute kidney injury (AKI) is a major organ failure in septic shock. Current medical tests (serum creatinine and urea) cannot identify AKI until approximately 48 hours after it occurs. Neutrophil gelatinase-associated lipocalin (NGAL) may be able to predict ischemic AKI more effectively and faster than serum creatinine and urea levels. The purpose of this study is to take a blood sample from patients at admission and then at 24 and 48 hours after to test their plasma for NGAL and compare the NGAL levels to their creatinine and urea levels. The investigators hypothesize that NGAL is an earlier marker to classify the kidney failure as acute tubular necrosis or pre-renal azotemia than creatinine and urea.

Detailed description

Primary Outcome Measures: To correlate elevated serum NGAL with the diagnosis of intrinsic acute kidney injury in septic shock Secondary Outcome Measures : To compare serum NGAL with serum creatinine, serum urea and urine output in septic AKI Death within the intensive care unit Death from all causes at 28 days after inclusion

Interventions

None listed

Sponsors

Inverness Medical Innovations
CollaboratorINDUSTRY
Université Victor Segalen Bordeaux 2
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients showing signs of infection and hypotension requiring the use of epinephrine despite of an appropriate fluid challenge. * 18 years of age or older

Exclusion criteria

* Age under 18 years * Prisoners or other institutionalized or vulnerable individuals * Participation in an interventional clinical study within the previous 30 days

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026